Trial Profile
A Phase 2 Study of GDC-0449 in Patients With Advanced Chondrosarcomas
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Aug 2023
Price :
$35
*
At a glance
- Drugs Vismodegib (Primary)
- Indications Chondrosarcoma
- Focus Therapeutic Use
- Acronyms CHONDROG
- 28 Jul 2023 Planned End Date changed from 30 Jun 2020 to 25 Jul 2024.
- 19 Dec 2022 Status changed to completed.
- 03 Aug 2018 Planned primary completion date changed from 30 Jun 2018 to 30 Jun 2019.